Intensity Financial Statements From 2010 to 2026

INTS Stock   0.40  0.01  2.44%   
Intensity Therapeutics' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Intensity Therapeutics' valuation are provided below:
Market Capitalization
23.7 M
Earnings Share
(0.55)
There are over one hundred nineteen available fundamental trends for Intensity Therapeutics, which can be analyzed over time and compared to other ratios. All traders should confirm Intensity Therapeutics' regular fundamentals against the performance from 2010 to 2026 and make sure the trends continue to evolve in the right direction. Market Cap is likely to drop to about 26.7 M in 2026. Enterprise Value is likely to drop to about 24.1 M in 2026
Check Intensity Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Intensity Therapeutics' main balance sheet or income statement drivers, such as Net Interest Income of 379.2 K, Interest Income of 379.2 K or Depreciation And Amortization of 21.4 K, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 7.93. Intensity financial statements analysis is a perfect complement when working with Intensity Therapeutics Valuation or Volatility modules.
  
Build AI portfolio with Intensity Stock
Check out the analysis of Intensity Therapeutics Correlation against competitors.

Intensity Therapeutics Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets6.4 M4.3 M8.2 M
Slightly volatile
Short and Long Term Debt Total150.8 K158.7 K620 K
Pretty Stable
Other Current Liabilities805.5 K457.2 K756.3 K
Slightly volatile
Total Current Liabilities3.4 MMM
Slightly volatile
Other Liabilities28.8 K32.4 K35.4 K
Slightly volatile
Property Plant And Equipment Net195.9 K109.8 K238.2 K
Slightly volatile
Accounts PayableM1.4 M685 K
Slightly volatile
CashM2.3 M4.2 M
Very volatile
Non Current Assets Total929.9 K1.6 M638.2 K
Slightly volatile
Non Currrent Assets Other1.6 M1.5 M403.1 K
Slightly volatile
Other Assets138.9 K192.9 K87 K
Slightly volatile
Cash And Short Term Investments2.2 M2.3 M7.1 M
Slightly volatile
Net Receivables53.8 K71.6 K44 K
Slightly volatile
Common Stock Shares Outstanding14.7 M16 M13.4 M
Slightly volatile
Liabilities And Stockholders Equity6.4 M4.3 M8.2 M
Slightly volatile
Non Current Liabilities Total94 K99 K1.9 M
Slightly volatile
Capital Lease Obligations203.1 K124.2 K246.6 K
Slightly volatile
Inventory25.1 K26.4 K146 K
Slightly volatile
Other Current Assets933.4 K889 K343.1 K
Slightly volatile
Other Stockholder Equity84.2 M80.2 M30.2 M
Slightly volatile
Total Liabilities1.6 M1.7 M3.8 M
Slightly volatile
Property Plant And Equipment Gross195.9 K109.8 K238.2 K
Slightly volatile
Total Current Assets5.8 MM7.6 M
Slightly volatile
Capital Stock1.2 K2.3 K1.1 K
Slightly volatile
Non Current Liabilities Other28.8 K32.4 K35.4 K
Slightly volatile
Short Term Debt30.6 K32.2 K479.1 K
Pretty Stable
Common Stock2.4 K2.3 K935
Slightly volatile
Property Plant Equipment389 K365.8 K296.7 K
Slightly volatile
Short and Long Term Debt3.5 MM2.7 M
Slightly volatile

Intensity Therapeutics Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Interest Income379.2 K361.1 K174.4 K
Slightly volatile
Depreciation And Amortization21.4 K22.5 K150.4 K
Slightly volatile
Selling General Administrative7.4 MM2.5 M
Slightly volatile
Other Operating Expenses9.6 M19.1 M7.8 M
Slightly volatile
Research Development6.6 M12.1 M5.5 M
Slightly volatile
Total Operating Expenses9.6 M19.1 M7.8 M
Slightly volatile
Cost Of Revenue21.4 K22.5 K149.6 K
Slightly volatile
Selling And Marketing Expenses117.6 K132.3 K144.4 K
Slightly volatile

Intensity Therapeutics Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation3.7 M3.5 M1.2 M
Slightly volatile
Begin Period Cash Flow5.5 M9.8 M4.1 M
Slightly volatile
Other Non Cash Items83 K87.4 K291.4 K
Slightly volatile
Change To Operating Activities179.9 K261.1 K150.1 K
Slightly volatile
Total Cash From Financing Activities3.2 M3.3 M4.7 M
Pretty Stable
End Period Cash FlowM2.3 M4.2 M
Very volatile
Change To Netincome814.3 KM743.9 K
Slightly volatile
Change To Account Receivables13.4 K15.1 K16.5 K
Slightly volatile
Depreciation130.4 K132.3 K169.7 K
Slightly volatile
Sale Purchase Of Stock2.8 M3.2 M3.5 M
Slightly volatile
Dividends Paid1.1 M1.2 M1.3 M
Slightly volatile
Other Cashflows From Investing Activities7.5 M8.5 M9.2 M
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Average Payables158.1 K177.8 K194.1 K
Slightly volatile
Inventory Turnover4.885.495.9908
Slightly volatile
Days Of Inventory On Hand47.8853.8758.7974
Slightly volatile
Payables Turnover0.02240.02360.2338
Slightly volatile
Average Inventory16 K16.9 K41.8 K
Slightly volatile
Cash Per Share0.160.170.5763
Pretty Stable
Days Payables Outstanding16.8 K16 K4.4 K
Slightly volatile
Income Quality0.91.080.8403
Slightly volatile
Current Ratio4.062.25.7283
Slightly volatile
Interest Debt Per Share0.00850.00890.0498
Pretty Stable
Debt To Assets0.02470.0260.202
Pretty Stable
Operating Cycle47.8853.8758.7974
Slightly volatile
Days Of Payables Outstanding16.8 K16 K4.4 K
Slightly volatile
Ebt Per Ebit0.820.880.9632
Very volatile
Effective Tax Rate3.0E-43.0E-43.0E-4
Slightly volatile
Quick Ratio3.992.25.6062
Slightly volatile
Net Income Per E B T0.790.880.9603
Slightly volatile
Cash Ratio2.821.72.9663
Slightly volatile
Days Of Inventory Outstanding47.8853.8758.7974
Slightly volatile
Debt Ratio0.02470.0260.202
Pretty Stable

Intensity Therapeutics Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap26.7 M28.1 M68.7 M
Slightly volatile
Enterprise Value24.1 M25.3 M65.2 M
Slightly volatile

Intensity Fundamental Market Drivers

Intensity Upcoming Events

12th of February 2024
Upcoming Quarterly Report
View
31st of December 2023
Next Fiscal Quarter End
View

About Intensity Therapeutics Financial Statements

Intensity Therapeutics shareholders use historical fundamental indicators, such as revenue or net income, to determine how well the company is positioned to perform in the future. Although Intensity Therapeutics investors may analyze each financial statement separately, they are all interrelated. The changes in Intensity Therapeutics' assets and liabilities, for example, are also reflected in the revenues and expenses on on Intensity Therapeutics' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Cost Of Revenue22.5 K21.4 K

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Intensity Stock Analysis

When running Intensity Therapeutics' price analysis, check to measure Intensity Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Intensity Therapeutics is operating at the current time. Most of Intensity Therapeutics' value examination focuses on studying past and present price action to predict the probability of Intensity Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Intensity Therapeutics' price. Additionally, you may evaluate how the addition of Intensity Therapeutics to your portfolios can decrease your overall portfolio volatility.